Thrombolytic Therapy: Future Issues

M M Samama; J Acar

doi:10.1055/s-0038-1642661

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1995; 74(01): 106-110
DOI: 10.1055/s-0038-1642661

Symposium

Thrombolytic Therapy

Schattauer GmbH Stuttgart

Thrombolytic Therapy: Future Issues

Authors

M M Samama

Service d’Hématologie Biologique, Paris, France
J Acar

Service de Cardiologie, Hôpital Tenon, France

Abstract

PDF Download

PDF (336 kb)

References

References
1 The GUSTO angiographic investigators. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary arteiy patency, ventricular function, and survival after myocardial infarction. New Engl J Med 1993; 329: 1615-1622
2 Topol EJ. Thrombolytic intervention. In Topol EJ. ed. Textbook of interventional cardiology Philadelphia Saunders 1989; 76-120
3 Hennekens CH. Thrombolytic therapy: pre- and post-GISSI-2, ISI-3, and GUSTO-1. Clinical Cardiology 1994; 17: 115-117
4 Bates ER, Topol E. Thrombolytic mortality trials. In: Thrombolysis and adjunctive therapy for acute myocardial infarction. Eric RBates. ed. Marcel Dekker, Inc; New York, Basel, Hong-Kong: 1993: 63-69
5 Collen D. Towards improved thrombolytic therapy. Lancet 1993; 342: 34-36
6 The European Myocardial Infarctus project group (EMIP group)101. Policy board : D. Julian (London), J. Lubsen (Rotterdam), M. Samama (Paris), P. Sleight (Oxford UK), G. Tognoni (Milan), and N. Victor (Heidelberg, Germany). Prehospital thrombolytic therapy in pateints with suspected acute myocardial infarction New Engl J Med. 1993 329. 383-389
7 Collen D, Stassen JM, Yasuda T, Refino C, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK, Bennett WF. Comparative thrombolytic properties of tissue-type plasminogen activator inhibitor-1 -resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1994; 72 (01) 98-104
8 Neuhaus KL, von Essen R, Vogt A, Tebbe U, Rustige J, Wagner HJ, Appel KF, Stienen U, Konig R, Meyer-Sabellek W. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction : results of the Genman Recombinant Plasminogen Activator Study. J Am Coll Cardiol 1994; 24 (01) 55-60
9 Bergum PW, Gardell SJ. Vampire bat salivary plasminogen activator exhibits a strict and fastidious requirement for polymeric fibrin as its cofactor, unlike human tissue-type plasminogen activator. J Biol Chem 1992; 267: 17726-17731
10 Collen D, Lijnen HR. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential. Blood 1994; 84 (03) 680-686
11 Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993; 87: 1850-1853
12 Verstraete M. Combination of urokinase and alteplase in the treatment of myocardial infarction. The urokinase and alteplase in myocardial infarction collaborative group. The URALMI group Cor ArtDis 1991; 2: 225-235
13 Topol EJ, Calif RM, George BS, Kerelakes DJ, Rothbaum D, Candela RJ, Abbotsmith CW, Pinkerton CA, Stump DC, Collen D, Lee KL, Pitt B, Kline EM, Boswick JM, O’Neill WW, Stack RS. TAMI Study group. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokianse in patients with acute myocardial infarction Circulation 1988; 77 (05) 1100-1107
14 Bode C, Meinhardt G, Runge MS, Freitag M, Nordt T, Arens M, Newell JB, Kiibler W, Haber E. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation 1991; 84 (02) 805-813
15 Dewerchin M, Collen D. Enhancement of the thrombolytic potency of plasminogen activators by conjugation with clot specific monoclonal antibodies. Bioconjug Chem 1991; 2 (05) 293-300
16 Bode C, Leinhardt G, Runge MS, Freitag M, Nordt T, Arens M, Newell JB, Kiibler W, Haber E. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation 1991; 84: 805-813
17 Robinson JH, Browne MJ, Carey JE, Chamberlain PD, Chapman CG, Cronk DW, Doss I, Entwisle C, Esmail AF, Kalinkdjian B, Lawrence GM P, McMurdo L, Mitchell D, Smith RA G, Wilson S. A recombinant, chimeric enzyme with a novel mechanism of action leading to greater potency and selectivity than tissue-type plasminogen activator. Circulation 1992; 86: 548-552
18 Underwood MJ, Pringle SW, de Bono DP. Reduction of thrombus formationin vivo using a thrombolytic agent targeted at damaged endothelial cells. Br J Surg 1992; 79: 915-917
19 More RS, Underwood MJ, de Bono DP. Targeting fibrinolytic agents to the vessel wall: a new therapeutic niche. Thromb Haemostas 1994; 1: 158-159
20 Torchilum VP, Papisons PM, Omerthova N, Belyaen A, Petrov AD, Ragomov SE. Magnetically driven thrombolysis preparations containing immobilized SK-targeted transport and action. Haemostasis 1988; 18: 113-116
21 Dawson KM, Cook A, Devine JM, Edwards RM, Hunter MG, Raper RH, Roberts G. Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents. J Biol Chem 1994; 269 (23) 15989-15992
22 Ellis SG, Tcheng JE, Navetta FI. et al. Safety and antiplateletect of murine monoclonal antibody 7E3 Fac directed against platelet glycoprotein Ilb-IIIa in patients undergoing elective coronary angioplasty. Coron Artery Dis 1993; 4: 167-176
23 Kleiman NS, Ohman EM, Keriakes DJ, Ellis NS, Ohman EM, Weisman HF, Topol EJ. Profound platelet inactivation with 7E3 shortly after thrombolytic therapy for acute myocardial infarction: Preliminary results of the TAMI8 Trial. Circulation 1991; 84 Supp.II 522-522 (abst)
24 The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb-IIIa receptor in high risk coronary angioplasty N Engl J Med 1993; 330: 956-961
25 Mousa SA, Bozarth JM, Forsythe MS, Jackson SM, Leamy A, Diemer MM, Kapil RP, Knabb RM, Mayo MC, Pierce SK, De Grado WF, Thoolen MJ, Reilly TM. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb-IIIa receptor antagonist. Circularion 1994; 89 (01) 3-12
26 Haskel EJ, Adams SP, Feigen LP, Saffitz JE, Gorczynski RJ, Sobel BE, Abendschein DR. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein Ilb-Illa receptor. Circulation 1989; 80: 1775-1782
27 Escudero C, Alavarez L, de Haro J, Gonzalez J, Alvarez MV, Millian I, Jorge-Herrero E, Castillo-Olivares JL. Prevention of arterial thrombosis by a monoclonal antibody against to 100 to 109 amino acid sequencer stretch of the beta-subunit of the human platelet fibrinogen receptor: A comparative study with low dose aspirin. J Am Coll Cardiol 1994; 23: 483-486
28 The RAPT Investigators. Randomized trial of Ridogrel, a combined thromboxane A2, synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction
29 Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemostas 1994; 72 (03) 381-386
30 Phaneuf MD, Ozaki CK JM T, Loza JP, Quist WC, LoGerfo FW. Covalent linkage of streptokinase to recombinant hirudin: a novel thrombolytic agent with antithrombotic properties. Thromb Haemostas 1994; 71 (04) 481-487
31 Samama M. Laboratory control of thrombolytic treatment of myocardial infarction with rt-PA. Fibrinolysis 1993; 7 (01) 46-47
32 Acar J, Dorent R, Vahanian A, Michel PL, Cormier B, Slama M, Cazaux P, Conard J, Verdy E, Samama M. Le risque hemorragique dans les traitements thrombolytiques par voie intraveineuse dans Tinfarctus myocardique aigu. Arch Mai Coeur 1988; 81 (01) 59-65
33 Tracy RP, Bovill EG. Fibrinolytic parameters and hemostatic monitoring: identifying and predicting patients at risk for major hemorrhag ic events. Am J Cardiol 1992; 69: 52-59 A
34 Sobel BE. Intracranial bleeding, fibrinolysis and anticoagulation. Causal connections and clinical implications. Circulation 1994; 90 (04) 2147-2152
35 Sane DC, Califf RM. Complications of thrombolytic therapy. In: Thrombolysis and adjunctive therapy for acute myocardial infarction. Bates ER. ed. Marcel Dekker Inc; New York, Basel, Hong-Kong: 1944: 91-115
36 Kase CS, O’Neal Am, Fischer M, Girgis GN, Ordia JI. Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis. Ann Intern Med 1990; 112: 17-21
37 Proner J, Rosenblum BR, Rothman A. Ruptured arteriovenous malformation complicating thrombolytic therapy with tissue plasminogen activator. Arch Neurol 1990; 47: 105-106
38 Harrington RA, Sane DC, Califf RM, Sigmon KN, Abbottsmith CW, Candela RJ, Lee K. Topol EJ for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Clinical importance of thrombocytopenia occuring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction J Am Coll Cardiol 1994; 23: 891-898
39 Melandri G, Branzi A, Traini AM, Semprini F, Cervi V, Magnani B. On the value of the activated clotting time for monitoring heparin therapy in acute coronary syndromes. Am J Cardiol 1993; 71: 469-471
40 Samama M, Horellou MH, Laaban JP, Conard J. Should thrombolytic therapy be used in pulmonary embolism. In: Fundamental and Clinical Fibrinolysis. Castellino FJ, Gaffney PJ, Samama MM, Takada A. Eds. Excerpta Medica; Amsterdam: 1987. 757 215-226
41 Goldhaber SZ. Evolving concepts in thrombolytic therapy for pulmonary embolism. Chest 1992; 101 suppl (Suppl. 04) 183S-185S
42 Goldhaber SZ. Role of echocardiography in diagnosing and treating pulmonary embolism. Proc Congr Angio Geneve’94 1994; abst 02-08 103
43 Goldhaber SZ, Sors H. Treatment of venous thrombosis and pulmonary embolism. In: Thrombosis in cardiovascular disorders. Fuster VF, Verstraete M, Saunders WB. Eds Philadelphia: 1992: 465-483
44 Wardlaw JM, Warlow CP. Thrombolysis in acute ischemic stroke: does it work. Stroke 1992; 23: 1826-1839
45 del Zoppo GJ. Thrombolytic therapy in stroke. In: Thrombolysis yearbook. Agnelli G. Ed. Excerpta Medica, Amsterdam: 1994: 113-135
46 Hommel M, Boissel JP, Comu C, Boutitie F, Lees KR, Besson G, Leys D, Amarenco P. Bogaert M for the MAST Study Group. Termination of trial of streptokinase in severe acute ischaemic stroke Lancet 1994; 345: 57-57